Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.45 |
| ▸ | HRH1 | P35367 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1995630 | 0.95 | ALDH1A1 (0.53) | ALDH1A1CYP1A2CYP3A4CYP2D6CHRM2 | |
| SCHEMBL1996447 | 0.94 | ALDH1A1 (0.60) | ALDH1A1CYP1A2CYP3A4CYP2D6CHRM2 | |
| SCHEMBL2248997 | 0.94 | ALDH1A1 (0.60) | ALDH1A1CYP1A2CYP3A4CYP2D6CHRM2 | |
| SCHEMBL2006723 | 0.92 | ALDH1A1 (0.56) | ALDH1A1CYP1A2CYP3A4CYP2D6CHRM2 | |
| SCHEMBL2003574 | 0.91 | ALDH1A1 (0.54) | ALDH1A1CYP1A2CYP3A4CYP2D6CHRM2 | |
| SCHEMBL1997498 | 0.90 | CYP3A4 (0.61) | ALDH1A1CYP1A2CYP3A4CYP2D6CHRM2 | |
| SCHEMBL1995595 | 0.89 | ALDH1A1 (0.52) | ALDH1A1CYP1A2CYP3A4CYP2D6CHRM2 | |
| SCHEMBL1998155 | 0.89 | ALDH1A1 (0.57) | ALDH1A1CYP1A2CYP3A4CYP2D6CHRM2 | |
| SCHEMBL1997866 | 0.88 | ALDH1A1 (0.53) | ALDH1A1CYP1A2CYP3A4CYP2D6CHRM2 | |
| SCHEMBL1994810 | 0.88 | ALDH1A1 (0.55) | ALDH1A1CYP1A2CYP3A4CYP2D6CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039489-B2 | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20110201583-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-7960385-B2 | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2011-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201583-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM1 | ALDH1A1 2899/4885CYP1A2 1577/4885CYP3A4 2788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.